TITLE

Pulmonary Hypertension: Diagnosis and Management

AUTHOR(S)
McGoon, Michael D.; Kane, Garvan C.
PUB. DATE
February 2009
SOURCE
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p191
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pulmonary arterial hypertension is a progressive, symptomatic, and ultimately fatal disorder for which substantial advances in treatment have been made during the past decade. Effective management requires timely recognition and accurate diagnosis of the disorder and appropriate selection among therapeutic alternatives. Despite progress in treatment, obstacles remain that impede the achievement of optimal outcomes. The current article provides an overview of the pathobiologic mechanisms of pulmonary arterial hypertension, including genetic substrates and molecular and cellular mechanisms, and describes the clinical manifestations and classification of pulmonary arterial hypertension. The article also reviews established approaches to evaluation and treatment, with emphasis on the appropriate application of calcium channel blockers, prostacyciin analogues, endotheiin receptor antagonists, and phosphodiesterase 5 inhibitors. in addition, the authors discuss unresolved issues that may complicate patient management, such as the clinical importance of mild or exercise-related pulmonary arterial hypertension, and they identify avenues by which treatment may advance in the future through the use of combination treatment, outcomes assessment, and exploration of alternative pharmacologic strategies.
ACCESSION #
36487127

 

Related Articles

  • Challenges in Endpoint Development for Pulmonary Hypertension Trials in Children. Ivy, Dunbar // Advances in Pulmonary Hypertension;2014, Vol. 13 Issue 3, p125 

    There are currently 12 medications approved for use in the treatment of pulmonary arterial hypertension (PAH) in adults. These include endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclins. However, in children there are no...

  • The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension. Harrington, Louise S.; Moreno, Laura; Reed, Anna; Wort, Stephen J.; Desvergne, Béatrice; Garland, Christopher; Lan Zhao; Mitchell, Jane A. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Background: Pulmonary vascular diseases are increasingly recognised as important clinical conditions. Pulmonary hypertension associated with a range of aetiologies is difficult to treat and associated with progressive morbidity and mortality. Current therapies for pulmonary hypertension include...

  • THERAPEUTIC APPROACHES FOR THE TREATMENT OF PULMONARY HYPERTENSION. Malaeb, Diana; Sakr, Fouad; Dabbous, Mariam // International Journal of Pharmacy;2013, Vol. 3 Issue 3, p436 

    Pulmonary hypertension is a progressive symptomatic fatal disease. It is a diagnosis of exclusion. The main goal of therapy is to lower pulmonary arterial pressure and pulmonary vascular resistance while preserving systemic pressure. Current treatments including calcium channel blockers,...

  • Trial watch: Phase III success for first-in-class pulmonary hypertension drug. Tse, Man Tsuey // Nature Reviews Drug Discovery;Dec2012, Vol. 11 Issue 12, p896 

    The article offers information on drug in the treatment of pulmonary hypertension(PH). It states that oral soluble guanylyl cyclase(sGC) stimulator riociguat generated high hope in the treatment of PH. The riociguat was evaluated in patients with pulmonary arterial hypertension(PAH) or in...

  • Pulmonary Hypertension. Mandel, Jess; Poch, David; Cotton, Deborah; Taichman, Damn; Williams, Sankey // Annals of Internal Medicine;5/7/2013, Vol. 158 Issue 9, p1 

    The article offers information about Pulmonary Hypertension and also reflects on its diagnostic methods, treatment strategies and prognosis. It states about the causes of the diseases which include heart failure, aortic valve disease and ventricular diastolic pressure. It mentions the diagnostic...

  • Treatment of Pulmonary Arterial Hypertension. Humbert, Marc; Sitbon, Olivier; Simonneau, Gérald // New England Journal of Medicine;9/30/2004, Vol. 351 Issue 14, p1425 

    Presents a review on the treatment of pulmonary arterial hypertension. Description of the disease; Pathophysiological features; National history and survival; Diagnostic classification; Functional classification of the disease; Therapeutic strategies such as the use of Calcium-channel blockers;...

  • Endothelin receptor antagonists and scleroderma related digital ulcers. Wha-Yong Lee; Faruqi, Shoaib; Morice, Alyn H. // Acta Reumatológica Portuguesa;jan-mar2013, Vol. 38 Issue 1, p58 

    No abstract available.

  • Chronic thromboembolic pulmonary hypertension: Medical treatment. Ozsu, Savas; Cinarka, Halit // Pulmonary Circulation;Apr-Jun2013, Vol. 3 Issue 2, p341 

    Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the...

  • Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension. Ito, Takayuki; Ozawa, Keiya; Shimada, Kazuyuki // Current Medicinal Chemistry;2007, Vol. 14 Issue 6, p719 

    During the last few decades, we have witnessed major improvements in the therapy of pulmonary arterial hypertension (PAH). PAH is characterized by abnormal remodeling of the pulmonary artery (PA) and increased PA pressures, resulting in a high premature mortality. Intravenous epoprostenol was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics